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Abstract
Objective: This study was undertaken to expand the phenotypic and genetic spectrum 
of CLCN4- related epilepsy and to investigate genotype– phenotype correlations.
Methods: We systematically reviewed the phenotypic and genetic spectrum of newly 
diagnosed and previously reported patients with CLCN4- related epilepsy. Three 
novel variants identified in four patients reported in this study were evaluated through 
in silico prediction and functional analysis by Western blot, immunofluorescence, and 
electrophysiological measurements.
Results: Epilepsy was diagnosed in 54.55% (24/44) of individuals with CLCN4- 
related disorders and was drug- resistant in most cases. Of 24 patients, 15 had epileptic 
encephalopathy and four died at an early age; 69.57% of patients had seizure onset 
within the first year of life. Myoclonic seizures are the most common seizure type, 
and 56.25% of patients presented multiple seizure types. Notably, seizure outcome 
was favorable in individuals with only one seizure type. All patients showed intellec-
tual disability, which was severe in 65.22% of patients. Additional common features 
included language delay, behavioral disorders, and dysmorphic features. Five patients 
benefitted from treatment with lamotrigine. Most variants, which were mainly mis-
sense (79.17%), were inherited (70.83%). Whereas frameshift, intragenic deletion, 
or inherited variants were associated with milder phenotypes, missense or de novo 
variants led to more severe phenotypes. All evaluated CLCN4 variants resulted in loss 
of function with reduced ClC- 4 currents. Nonetheless, genotype– phenotype relation-
ships for CLCN4- related epilepsy are not straightforward, as phenotypic variability 
was observed in recurrent variants and within single families.
Significance: Pathogenic CLCN4 variants contribute significantly to the genetic 
etiology of epilepsy. The phenotypic spectrum of CLCN4- related epilepsy includes 
drug- resistant seizures, cognitive and language impairment, behavioral disorders, and 
congenital anomalies. Notably, the mutation type and the number of seizure types 
correlate with the severity of the phenotype, suggesting its use for clinical prognosis. 
Lamotrigine can be considered a therapeutic option.
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1 |  INTRODUCTION
The CLC gene family contains nine members in mammals, 
four of which encode plasma membrane chloride channels 
(ClC- 1, ClC- 2, ClC- Ka, ClC- Kb) and five intracellular 
2Cl−/H+ exchangers (ClC- 3– 7).1,2 Dysfunction of some 
of these leads to severe neurological disorders, including 
leukodystrophy, neurodegeneration, intellectual disability 
(ID), epilepsy, and lysosomal storage disease for ClC- 2, 
ClC- 3, ClC- 4, ClC- 6, and ClC- 7,3– 16 highlighting the piv-
otal role of CLC proteins in the central nervous system. 
ClC- 4, which is encoded by the CLCN4 (Online Mendelian 
Inheritance in Man database # 302910) gene located on 
human chromosome Xp22.2, is a voltage- dependent 2Cl−/
H+ exchanger.17– 19 Its precise physiological function is 
unclear, but ClC- 4 is likely to be involved in the ion ho-
meostasis of endosomes and intracellular trafficking.20– 23 
ClC- 4 is broadly expressed across tissues, including brain, 
skeletal muscle, liver, kidney, intestine, and heart. In brain, 
it is prominently found in hippocampus and cerebellum.11,24 
Mutations in the CLCN4 gene have been found to underlie 
X- linked ID, epilepsy, behavior disorder, and dysmorphic 
features.6,8,12,15 In 2013, a de novo loss- of- function muta-
tion (p.Gly544Arg) in CLCN4 was first reported to cause 
early onset epileptic encephalopathy (EE) and severe de-
velopmental delay (DD).12 Subsequently, five new CLCN4 
variants were detected in five families with ID and/or epi-
lepsy.6 As massive parallel sequencing has expanded, in-
creasingly more variants in this gene have been reported 
in association with supplementary phenotypic features and 
a range of severity. To date, there is a lack of systematic 
investigation of the spectrum of seizure semiology and 
genotype– phenotype correlations in subjects with CLCN4- 
related epilepsy. In this study, we characterized the func-
tional effects of newly identified variants. Furthermore, we 
assessed the clinical data of four unreported and all pre-
viously reported patients with CLCN4- related epilepsy to 
delineate the clinical features and molecular genetic find-
ings and to assess genotype– phenotype relationships.
2 |  MATERIALS AND METHODS
2.1 | Subjects
Four subjects from four unrelated families with epilepsy of 
unknown etiology were analyzed. All patients were clini-
cally evaluated and underwent whole exome sequencing 
(WES). This study was approved by the Ethics Committee of 
Xiangya Hospital of Central South University, China (human 
study/protocol # 201603205) and performed in accordance 
with the ethical standards laid down in the Declaration of 
Helsinki. Written informed consent was obtained from the 
parents of all subjects.
2.2 | Sequencing and bioinformatic 
analysis of novel CLCN4 variants
The sequencing of genomic DNA from peripheral blood 
and the bioinformatic analysis of the CLCN4 variants are 
described in detail in the Supplementary Materials. Clinical 
significance of novel variants was determined using the 
American College of Medical Genetics and Genomics 
(ACMG) standard guidelines.25
2.3 | Systematic literature review
We conducted a systematic literature review focused on 
CLCN4- related epilepsy by searching the PubMed database 
using the keywords "CLCN4", "ClC- 4", and "epilepsy". All 
publications were reviewed for case series or cohort studies 
that contained clinical data on patients with CLCN4 variants. 
Award Number: 81771409 and 81771408; 
China Scholarship Council fellowship; 
German Federal Ministry of Research 
and Education, Grant/Award Number: 
031A314
K E Y W O R D S
behavior disorders, Cl−/H+ exchanger, ClC- 4, intellectual disability, seizure
Key Points
• All individuals with pathogenic CLCN4 variants should be evaluated for epilepsy 
due to the high prevalence of seizures
• CLCN4- related epilepsy has a wide phenotypic spectrum, varying from mild brief 
absence seizures to severe EE
• Mutation type and number of seizure types correlate with phenotype severity, but 
genotype– phenotype relationships are not straightforward
• Some patients benefited from treatment with lamotrigine, which should be consid-
ered as a therapeutic option in the future
• All evaluated CLCN4 variants resulted in loss of function
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Individuals were included if they had a pathogenic CLCN4 
variant and their phenotype included epileptic seizures. We 
rechecked all the variants with nucleotide and amino acid 
numbering according to the CLCN4 reference transcript 
NM_001830.3 (reference protein NP_001821.2). We system-
atically reviewed the detailed clinical, molecular genetics, 
and functional characterization of the previously reported and 
newly identified individuals with CLCN4- related epilepsy.
2.4 | In vitro functional assessment of novel 
CLCN4 variants
To assess the effect of the three novel ClC- 4 variants, we 
performed Western blot analysis of expression levels, im-
munofluorescence imaging of subcellular localization, and 
electrophysiological measurements upon heterologous ex-
pression, as previously described6,26,27 and detailed in the 
Supplementary Materials.
3 |  RESULTS
3.1 | Identification of CLCN4 variants in 
four families
Using trio- based WES, we identified three novel (p.Val455Ile, 
p.Thr532Lys, p.Leu625Phe) and one previously reported 
(p.Arg718Trp) CLCN4 variants. All probands suffered from 
severe ID and intractable EE. No pathogenic variation was 
found in other epilepsy or ID candidate genes (detailed clini-
cal information is given in the Supplementary Materials). The 
p.Thr532Lys variant affects a highly conserved residue of 
the helical intramembrane domain , the p.Leu625Phe variant 
substitutes a conserved residue in the first cystathionine- β- 
synthase (CBS) domain, and the p.Val455Ile variant alters a 
less conserved residue of the helical transmembrane domain 
(Figure 1 and Figure S1). The p.Thr532Lys and p.Leu625Phe 
variants were not present in any database (Table 1). The 
pathogenicity of p.Thr532Lys and p.Leu625Phe variants 
was classified as likely pathogenic in accordance with the 
ACMG guideline (Table 1). Although the p.Val455Ile vari-
ant had a very low frequency in gnomAD, ExAC, 1000 
Genomes, and ESP6500, it is predicted to be benign (Table 
1). The p.Arg718Trp variant was recently reported in two 
patients.8,15
3.2 | Phenotypic spectrum of patients with 
CLCN4 variants
To date, a total of 40 individuals with CLCN4- related dis-
orders have been reported.6,8,12,15,28 Twenty of them had 
epilepsy and are the subjects of this study. Therefore, with 
our four patients, the total number of patients with CLCN4- 
related epilepsy known to date is 24. Thus, epilepsy was 
F I G U R E  1  Schematic representation of ClC- 4 topology and gene exon structure. The position of previously published and three novel CLCN4 
variants identified in CLCN4- related epilepsy are indicated. Triangles indicate frameshift, circles missense, and squares intragenic copy number 
deletion. The numbers in parentheses refer to the number of respective patients
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diagnosed in 54.55% (24/44) of individuals with CLCN4- 
related disorders at the time of reporting. The clinical fea-
tures of the 24 patients with epilepsy are summarized in 
Table 2. As expected, males are more often affected than 
females, with 87.5% (21/24) of individuals being male and 
12.5% (3/24) female. However, female patients can be as se-
verely affected as the male counterparts. The seizure onset, 
ranging from neonatal to 14  years (data available for 23), 
was detected within the first year of life in 69.57% of pa-
tients. The majority (62.5%, 15/24) of affected individuals 
developed EE. Of the 15 patients with EE, four developed 
infantile spasms (IS), and one developed epilepsy of infancy 
with migrating focal seizures (EIMFS). The seizure types 
were available for review in 16 patients. Seven (43.75%) in-
dividuals had only one type of seizure, and nine (56.25%) 
patients showed multiple seizure types. Seizure semiology is 
variable, including myoclonic, absence, IS, tonic, complex 
partial, tonic– clonic, focal, and secondary generalized sei-
zures. Myoclonic seizures, occurring in seven patients, were 
the most common seizure type.
In addition to the variability of the epilepsy phenotype, 
seizure outcome varied. One patient had brief absence sei-
zures that did not require treatment. Twenty- three patients 
received antiseizure therapy. Thirteen of 23 (56.52%) pa-
tients were drug- refractory with at least two drugs failing 
that were appropriately applied.29 Only 30.43% (7/23) were 
controlled on monotherapy, and three (13.04%) remitted 
after polytherapy. Seizures were refractory in all individuals 
with EE, and four patients died at an early age (2.75, 12, 16, 
and 19  years). In the EE group, four had IS, and three of 
them received adrenocorticotropic hormone therapy, which 
showed transient effectiveness in two of the three patients. 
Four patients were treated with a ketogenic diet in combina-
tion with other antiepileptic drugs (AEDs), which showed 
transient or no effectiveness on seizures. Of note, seizure 
outcome was favorable in individuals with only one seizure 
type, as seizures were controlled well with monotherapy or 
even without pharmacotherapy in all patients except one, 
whose seizures were controlled on polytherapy. Conversely, 
all nine individuals with multiple seizure types required 
two or more AEDs, and only two patients remitted. There 
is no established therapy for CLCN4- related epilepsy, and 
no superior medication was identified. Two (p.Val455Ile, 
p.Leu625Phe) patients with IS in this study had a trial of la-
motrigine with good clinical response. One patient became 
seizure- free, and one showed dramatic improvement after 
other drugs had failed. Three previously reported individu-
als (one p.Gly544Arg, two p.Val536Met)8 also showed sig-
nificant improvement with the addition of lamotrigine. One 
patient was well controlled on carbamazepine monotherapy. 
By contrast, treatment with valproic acid was not effective 
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3.3 | Developmental, behavioral, 
neurologic, and facial features
Cognitive development has been monitored in all 24 cases 
with CLCN4- related epilepsy, and five patients showed de-
velopmental regression after seizure onset. Cognition be-
fore seizure onset varied from normal to severely delayed, 
and was abnormal during follow- up in all patients. Fifteen 
of 23 patients (65.22%) for whom information on cogni-
tion was available had severe ID; ID was moderate in six 
(26.08%) and mild in two cases (8.7%). Cognitive outcome 
was worse in patients with epilepsy than in those without epi-
lepsy. Severe ID was observed in 15 of 23 (65.22%) patients 
with CLCN4- related epilepsy and in five of 20 (25%) pa-
tients carrying pathogenic CLCN4 variants without epilepsy. 
Moreover, patients with severe seizures showed more severe 
cognitive impairment. However, cognition did not improve 
in most patients after seizures were controlled. Language 
delay was observed in 10 patients (41.67%, 10/24), and 25% 
(6/24) were nonverbal.
Neurologic examination showed anomalies in most pa-
tients. Microcephaly, defined as occipitofrontal circumfer-
ence in the 3rd percentile or smaller, was observed in seven 
individuals (30.43%, 7/23). Six of them (85.71%, 6/7) devel-
oped EE. Infantile hypotonia, often more prominent in the 
limbs, was found in seven patients (29.17%). Additional neu-
rologic features included hyperreflexia, nystagmus, spastic 
quadriplegia, extrapyramidal signs, and cerebellar symptoms. 
Other growth parameters, such as weight and height, were 
in the normal range for most patients. Behavioral disorders 
occurred in 10 patients (43.48%, 10/23), including aggres-
sion (30.43%, 7/23), autistic features (8.7%), hyperactivity 
(8.7%), self- abusive behavior (4.35%), irritability (4.35%), 
depressive disorder (4.35%), apathy and social disinhibition 
(4.35%), and bipolar disorder (4.35%). A variety of subtle 
facial dysmorphic features were noted in 15 patients (65.22%, 
15/23). Notably, although most patients showed facial dys-
morphisms, and the common facial features were long face, 
broad nasal bridge, and prominent chin, there was no recog-
nizable facial pattern nor any facial features typical for patho-
genic CLCN4 variants.
3.4 | Electroencephalographic and magnetic 
resonance imaging features
Electroencephalography (EEG) and neuroimaging were also 
variable with no consistent findings. EEG data were avail-
able for 14 patients; 11 individuals (78.6%, 11/14) displayed 
epileptiform discharges, and three of them remitted. Three 
patients without epileptiform discharges were controlled 
on monotherapy. The spectrum of EEG abnormalities was 
wide, and no specific EEG abnormalities were found. Slow 
background activity and multifocal spike- and- slow waves 
were the most common patterns observed on EEG. Three 
patients with IS showed an hypsarrhythmia EEG, and one 
patient showed IS without hypsarrhythmia. Neuroimaging 
was available for review in 15 patients and showed brain 
structural abnormalities in 12 (80%, 12/15) individuals. The 
most common abnormalities were corpus callosum hypo-
plasia (46.67%, 7/15) and white matter changes (46.67%). 
Ventriculomegaly was observed in four cases. Cerebellar at-
rophy was evident in three cases and cerebral atrophy in two 
cases. Delayed myelination was evident in two patients who 
were imaged after 3 months of age. Other findings include 
small perivascular spaces, small hippocampus, enlarged sub-
arachnoid spaces, and subcortical fluid- attenuated inversion 
recovery/T2 hyperintensity.
3.5 | Molecular genetics
Nine different variants were reported previously for the 20 
patients with CLCN4- related epilepsy. In this study, we 
identified three novel variants (p.Val455Ile, p.Thr532Lys, 
p.Leu625Phe), and one previously reported variant 
(p.Arg718Trp). Thus, a total of 12 distinct CLCN4 variants 
have been identified in 24 patients from 15 independent fam-
ilies (Table 3). Most variants (70.83%, 17/24) were inherited, 
and seven variants arose de novo, including in one patient 
who was mosaic. The most common types of variants are 
missense variants (79.17%, 19/24), followed by frameshift 
variants (12.5%, 3/24) and a small intragenic copy number 
deletion (8.33%, 2/24). In total, only two variants were re-
current, including p.Gly544Arg in two and p.Arg718Trp in 
three patients. The ClC- 4 protein is a dimer with two identi-
cal subunits, each of which contains a pore responsible for 
the selective coupling of the Cl− flux to H+ countertrans-
port.1 Each subunit contains 18 α- helices and two CBS do-
mains. Four variants mapped to the helical intramembrane 
domain (H- IM) (p.Val275Met, p.Thr532Lys, p.Ser534Leu, 
p.Val536Met), one to the helical transmembrane domain 
(H- TM) (p.Val455Ile), one to the cytoplasmic region 
(p.Asp15Serfs*18), two to the loop domain (p.Leu221Val, 
p.Gly544Arg), and four to the CBS domain (p.Leu625F, 
p.Ile626Asnfs*135, chrX: g.[10182428_10187807]_
[10189796_ 10201480] delete maternal, p.Arg718Trp; 
Figure 1). The CLCN4 gene is composed of 13 exons, and 
variants were identified in Exons 11 (50%), 12 (16.67%), 3 
(8.33%), 7 (8.33%), 8 (8.33%), and 9 (8.33%), whereas no 
variants were reported for Exons 1, 2, 4, 5, 6, and 10. To 
date, functional studies have been performed for six mis-
sense variants (p.Leu221Val, p.Val275Met, p.Ser534Leu, 
p.Val536Met, p.Gly544Arg, p.Arg718Trp). All evaluated 
CLCN4 variants resulted in loss of function with significantly 
reduced current amplitude.6,8
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T A B L E  2  Clinical details of patients with CLCN4- related epilepsy






circumference Height Weight Seizure onset Seizure types EE
Seizure- related 
death Speech abilities
Asp15Serfs*18 Belgian Male 52 years 1 1 50th– 97th centile 25th– >98th 
centile
75th– 90th centile NR Absence No No LD
Leu221Val Anglo- Australian Male 16 years 1 1 50th centile 25th– 50th centile 25th−50th centile Infancy CP No No Severe LD
Val275Met Anglo- American Female 10 years 1 1 25th centile 25th– 50th centile 75th centile 13 months GS, M, CP Yes No NV
Val455Ile Chinese Male 3 years 7 months 1 1 50th– 75th centile <3rd centile <3rd centile Neonatal IS, M, GT, FS Yes, IS No NV
Thr532Lys Chinese Male 2 years 9 months 1 1 <3rd centile <3rd centile <3rd centile 2 months IS, M, GT Yes, IS Yes, 2 years 
9 months
NV
Ser534Leu Northern European Male 3 years 1 1 <3rd centile 75th– 90th centile 75th– 90th centile 3 months IS, M, T, absence Yes, IS No LD





8 1 50th– 98th centile 25th– >98th 
centile
3rd−75th centile Infancy/early 
childhood (8)
CP, GTC, atonic Yes (5), no (3) Yes (3/8), 12 years, 
16 years, 
19 years
LD (4), normal (4)
Gly544Arg Dutch (1),
North American (1)
2 male 14 months, 10 years 2 2 2nd centile <1st centile (1), 
NA (1)




Absence, GTC (1), CP, 
secondary GS (1)
Yes (2) No (2) NV (1), NR (1)
Leu625Phe Chinese Male 5 years 1 1 75th– 98th centile 3rd−15th centile 15th– 25th centile 5 months IS, M, GTC Yes, IS No Severe LD




Hispanic 2 male 14 years, 15 years 2 1 3rd– >98th centile 50th– 95th centile 50th centile 6 months (1), 
14 years (1)
FS, GS, M (1), GTC (1) Yes (1), no (1) No (2) Severe LD (2)




3 3 <3rd−75th centile 
(2), NR (1)
85th– 75th centile 
(1), NR (2)









No (3) NV (2), NR (1)
Variants Level of ID Regression Infantile hypotonia Hypertonia Other neurological features Behavioral issues Facial dysmorphism Other issue
Asp15Serfs*18 Moderate No No No Shuffling gait Aggression Long face, PC No
Leu221Val Moderate No Yes No Clumsiness and fatigue on walking Depressive disorder Long face Gastroesophageal reflux, 
asthma
Val275Met Severe Yes No Yes Increased peripheral tone, brisk 
patella reflexes, ABS
No No No
Val455Ile Severe No Yes No Tendon hyporeflexia, ABS Repetitive patting on the head Long face, BSF, DNB No
Thr532Lys Severe No No Yes Nystagmus No Long face Right inguinal hernia, 
congenital laryngeal 
chondrodysplasia
Ser534Leu Severe No Yes Yes CVI, evolving upper limb hypertonia 
and spasticity
No Round face, small pointed chin FD, recurrent aspiration, 
capillary hemangioma
Val536Met Mild (1), moderate (2), 
severe (5)
Yes (1), no (7) Yes (1), no (7) No (8) PS, unsteady gait (2), diplegia (2), 
ataxia (1)
Aggression (3), hyperactivity (1), 
bipolar disorder (1), no (5)
Long face, PC, slightly "coarse" 
facial features, DNB (4), no (4)
No
Gly544Arg Severe (2) No (2) Yes (1), no (1) No (2) Dystonic posturing (1), PS, unsteady 
gait (1)
Apathy, social disinhibition, 
motor stereotypies (1), no (1)
Round face, downsloping palpebral 
fissures, open mouth (1), NR 
(1)
FD (1), NR (1)
Leu625Phe Severe Yes No No Unsteady gait Aggression, hyperactivity, 
irritability
Congenital left upper eyelid ptosis No
Ile626Asnfs*135 Moderate (2) No (2) No (2) No (2) No (2) Aggression (2) Long face, PC, lean body habitus 
(2)
No (2)
chrX: g.(10182428- 10187807) 
_(10189796_10201480) del mat
Severe (1), mild (1) Yes (1), no (1) Yes (1), no (1) No (2) Gait abnormality, CVI, 
nonprogressive upper limb 
choreiform movements (1), no (1)
No (2) High arched palate (1), no (1) No (2)
Arg718Trp Severe (2), NR (1) Yes (1), no (2) Yes (1), no (2) Yes (1), no (2) ABS (1), NR (2) Drooling, some self- abusive 
behavior (1), no (1), NR (1)
BSF, deep set eyes, wide philtrum, 
full lower lip (1), no (2)
FD, scoliosis (1), no (2)
(Continues)
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death Speech abilities
Asp15Serfs*18 Belgian Male 52 years 1 1 50th– 97th centile 25th– >98th 
centile
75th– 90th centile NR Absence No No LD
Leu221Val Anglo- Australian Male 16 years 1 1 50th centile 25th– 50th centile 25th−50th centile Infancy CP No No Severe LD
Val275Met Anglo- American Female 10 years 1 1 25th centile 25th– 50th centile 75th centile 13 months GS, M, CP Yes No NV
Val455Ile Chinese Male 3 years 7 months 1 1 50th– 75th centile <3rd centile <3rd centile Neonatal IS, M, GT, FS Yes, IS No NV
Thr532Lys Chinese Male 2 years 9 months 1 1 <3rd centile <3rd centile <3rd centile 2 months IS, M, GT Yes, IS Yes, 2 years 
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NV
Ser534Leu Northern European Male 3 years 1 1 <3rd centile 75th– 90th centile 75th– 90th centile 3 months IS, M, T, absence Yes, IS No LD
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3rd−75th centile Infancy/early 
childhood (8)
CP, GTC, atonic Yes (5), no (3) Yes (3/8), 12 years, 
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FS, GS, M (1), GTC (1) Yes (1), no (1) No (2) Severe LD (2)
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(2), NR (1)
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No (3) NV (2), NR (1)
Variants Level of ID Regression Infantile hypotonia Hypertonia Other neurological features Behavioral issues Facial dysmorphism Other issue
Asp15Serfs*18 Moderate No No No Shuffling gait Aggression Long face, PC No
Leu221Val Moderate No Yes No Clumsiness and fatigue on walking Depressive disorder Long face Gastroesophageal reflux, 
asthma
Val275Met Severe Yes No Yes Increased peripheral tone, brisk 
patella reflexes, ABS
No No No
Val455Ile Severe No Yes No Tendon hyporeflexia, ABS Repetitive patting on the head Long face, BSF, DNB No
Thr532Lys Severe No No Yes Nystagmus No Long face Right inguinal hernia, 
congenital laryngeal 
chondrodysplasia
Ser534Leu Severe No Yes Yes CVI, evolving upper limb hypertonia 
and spasticity
No Round face, small pointed chin FD, recurrent aspiration, 
capillary hemangioma
Val536Met Mild (1), moderate (2), 
severe (5)
Yes (1), no (7) Yes (1), no (7) No (8) PS, unsteady gait (2), diplegia (2), 
ataxia (1)
Aggression (3), hyperactivity (1), 
bipolar disorder (1), no (5)
Long face, PC, slightly "coarse" 
facial features, DNB (4), no (4)
No
Gly544Arg Severe (2) No (2) Yes (1), no (1) No (2) Dystonic posturing (1), PS, unsteady 
gait (1)
Apathy, social disinhibition, 
motor stereotypies (1), no (1)
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choreiform movements (1), no (1)
No (2) High arched palate (1), no (1) No (2)
Arg718Trp Severe (2), NR (1) Yes (1), no (2) Yes (1), no (2) Yes (1), no (2) ABS (1), NR (2) Drooling, some self- abusive 
behavior (1), no (1), NR (1)
BSF, deep set eyes, wide philtrum, 
full lower lip (1), no (2)
FD, scoliosis (1), no (2)
(Continues)
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3.6 | Genotype– phenotype correlations
Frameshift or intragenic deletion variants are associated 
with milder epileptic phenotypes, and seizures were easily 
controlled compared with most individuals with missense 
variants. The majority (4/5) of individuals with frameshift or 
intragenic deletion variants were controlled on monotherapy, 
whereas only 21.05% (4/19) of patients with missense vari-
ants achieved this with monotherapy or no treatment, and 
four of them died before the age of 19  years. In addition, 
the degree of ID was greater in individuals with missense 
variants. Severe ID was observed in 20% (1/5) of cases with 
frameshift or intragenic deletion variants and in 77.78% 
(14/18) of cases with missense variants. Hence, phenotypes 
of individuals with frameshift or intragenic deletion variants 
were relatively mild compared with the majority of individu-
als with missense variants. In comparison to inherited vari-
ants, de novo variants were more prone to cause more severe 
phenotypes. All patients with de novo variants had severe 
ID, and 85.71% (6/7) of these had intractable EE. In con-
trast, inherited variants are less frequently found among pa-
tients with severe ID (52.94%, 9/17) and EE (52.94%, 9/17). 
We observed no definite correlation between the location 
of the variants and the severity of the associated phenotype. 
Even with the same variant, a large phenotypic variance is 
observed. This is exemplified by the recurrent p.Arg718Trp 
variant, which has now been described in three unrelated pa-
tients, two in previous studies8,15 and one here. Of the three 
patients, one had brief absence seizures with onset at 8 years 
of age and no need of treatment. In contrast, two suffered 
from intractable EE starting at the age of 1 month. This vari-
ability was illustrated by a considerable intrafamilial vari-
ability in disease severity. For example, eight patients from 
one family carrying the same variant (p.Val536Met) had 
distinct phenotypes.6,8 Drug- resistant epilepsy was present in 
six individuals and early death occurred in three individuals, 
possibly because of limited antiepileptic treatment options.8 
However, seizures were controlled on monotherapy in two 
individuals. In addition, they also showed different degrees 
of ID, which was evaluated as severe in five patients, moder-
ate in two, and mild in one.
3.7 | Functional findings of three novel 
CLCN4 variants
To investigate the functional consequences of the three novel 
ClC- 4 variants, we first tested their protein levels by Western 
blot analysis. The three mutant proteins were expressed at 
levels similar to wild- type (WT) ClC- 4- FLAG in HEK293 
Variants EEG Neuroimaging Response to treatment
Asp15Serfs*18 No epileptiform activity Not tested Well controlled on monotherapy, medication ceased by 7 years
Leu221Val Mildly abnormal due to SB Small perivascular spaces seen in the inferior aspects of the putamen 
bilaterally
Well controlled on carbamazepine monotherapy
Val275Met High- amplitude discharges with excessive generalized SB and absence of posterior 
rhythm
Persistently enlarged 3rd ventricle, nonspecific subcortical FLAIR/T2 
hyperintensity left frontal region
Refractory to polytherapy
Val455Ile Multifocal spike wave, SSW, PSSW, AH, SB Periventricular leukomalacia Refractory to polytherapy
Thr532Lys Multifocal spike wave, SSW, PSSW, AH CCH white matter reduction in posterior horn of lateral ventricle Refractory to polytherapy
Ser534Leu Focal activity evolving to intermittent multifocal spikes and generalized SB Periventricular WML with compensatory dilation of lateral and third 
ventricles
Refractory to polytherapy
Val536Met Potentially epileptogenic activity throughout recording (1), not tested (7) Marked supra- and infratentorial atrophy, TCC, CA (2), 
ventriculomegaly (1), cortical atrophy, WML (1), not tested (6)
Well controlled on monotherapy (2), refractory to polytherapy (6)
Gly544Arg SB, temporal spikes (1), high- amplitude spikes, generalized spike and polyspike 
waves (1)
CCH, increased FLAIR signal in white matter (1), normal (1) Refractory to polytherapy until lamotrigine added (1), refractory (not 
fully responsive to medications) at 14 months (1)
Leu625Phe Multifocal or generalized sharp waves, spike waves, SSW, polyspike waves IH Normal (2 years), CA (4 years) Refractory to polytherapy until lamotrigine added
Ile626Asnfs*135 Not tested (2) Not tested (2) Controlled on monotherapy medication ceased by 7– 10 years of age (2)
chrX: g.(10182428_10187807)_(10189796_10201480) del 
mat
Bioccipital spikes, generalized spikes, generalized SB (1), normal (1) DM, TCC, global cerebral atrophy, particularly affecting the cerebral 
white matter (1), normal (1)
Refractory to polytherapy (1), controlled on levetiracetam 
monotherapy (1)
Arg718Trp SB, IH, multifocal spike waves, PSSW, SSW (1), multifocal discharges (1), not 
tested (1)
TCC (2), white matter reduction, small left hippocampus, left 
ventriculomegaly, DM (1), normal (1)
Refractory to polytherapy, but one finally remitted (2), not treated (1)
Abbreviations: ABS, abnormal Babinski signs; AH, atypical hypsarrhythmia; BSF, broad square forehead; CA, cerebellar atrophy; CCH, corpus callosum hypoplasia;  
CP, complex partial; CVI, cortical visual impairment; DM, delayed myelination; DNB, depressed nasal bridge; EE, epileptic encephalopathy; EEG,  
electroencephalogram; EIMFS, epilepsy of infancy with migrating focal seizures; FD, feeding difficulties; FLAIR, fluid- attenuated inversion recovery; FS, focal  
seizures; GS, generalized seizures; GT, generalized tonic; GTC, generalized tonic– clonic; ID, intellectual disability; IH, intermittent hypsarrhythmia; IS, infantile  
spasms; LD, language delay; M, myoclonic; NA, not available; NR, not reported; NV, nonverbal; PC, prominent chin; PS, progressive spasticity; PSSW, polyspike  
and slow waves; SB, slow background; SSW, spike and slow waves; T, tonic; TCC, thin corpus callosum; WML, white matter loss.
T A B L E  2  (Continued)
   | 1409HE Et al.
cells (Figure 2A). To test for the functionality of the ClC- 4 
variants, we performed electrophysiological recordings of 
WT and mutant ClC- 4 in HEK293 T cells. All three novel 
variants yielded drastically reduced outwardly rectifying 
currents compared to WT, demonstrating loss of function 
(Figure 2B,C). We next assessed the subcellular localiza-
tion of the ClC- 4 variants upon heterologous expression in 
HEK293T cells. In agreement with previous reports,23,30 WT 
ClC- 4 localized predominantly to the endoplasmic reticulum 
(ER), which was positive for the coexpressed marker cal-
nexin (Figure 2D). ClC- 4, seemingly devoid of endosomal 
localization signals,31 can heterodimerize with its paralogue 
ClC- 3,30 enabling the transport of ClC- 3/ClC- 4 dimers from 
the ER to endosomal– lysosomal compartments.23,30,32 When 
we coexpressed WT ClC- 4 with ClC- 3b in HEK293T, both 
proteins expectedly colocalized to slightly enlarged endo-
somal compartments (Figure 2D). The three ClC- 4 vari-
ants colocalized with ClC- 3b, demonstrating that the ability 
to heterodimerize was not impaired. However, in addition 
to the vesicular localization, we observed a slightly more 
pronounced residual reticular pattern of ClC- 3b/ClC- 4 for 
ClC- 4 variants than for WT (Figure 2E). This might be due 
to stronger ER retention of mutant ClC- 4 and contribute to 
the loss of function observed in the electrophysiological 
measurements.
4 |  DISCUSSION
Pathogenic CLCN4 variants have been reported in patients 
with X- linked ID, epilepsy, behavioral disorder, and dys-
morphic features. As expected for an X- linked disease, fe-
males are less often affected. However, the affected females 
can develop as severe phenotypes as males. The underlying 
complexity of X- chromosome inactivation in cells and tis-
sues33 hinders a prediction of the outcome. So far, CLCN4 
variants have been reported in 40 individuals, and 20 of them 
presented with epilepsy.6,8,12,15 Here, we identified three 
novel and one previously reported CLCN4 variant. All four 
patients displayed global DD and EE. Bioinformatics analy-
sis and functional study supported the deleterious effect in 
p.Thr532Lys and p.Leu625Phe variants. For p.Val455Ile, 
the prediction tools suggest a benign variant. However, this 
variant segregated in the family, and WES showed no other 
likely pathogenic variants. Importantly, electrophysiological 
measurements showed that this variant caused a marked re-
duction of ClC- 4 currents, supporting the pathogenicity of 
this variant. Combining our series with previously published 
cases, epilepsy was diagnosed in 54.55% of the subjects with 
CLCN4 variants, suggesting that all individuals with patho-
genic CLCN4 variants should be evaluated for epilepsy due 
to the high prevalence of seizures in this population. Our 
Variants EEG Neuroimaging Response to treatment
Asp15Serfs*18 No epileptiform activity Not tested Well controlled on monotherapy, medication ceased by 7 years
Leu221Val Mildly abnormal due to SB Small perivascular spaces seen in the inferior aspects of the putamen 
bilaterally
Well controlled on carbamazepine monotherapy
Val275Met High- amplitude discharges with excessive generalized SB and absence of posterior 
rhythm
Persistently enlarged 3rd ventricle, nonspecific subcortical FLAIR/T2 
hyperintensity left frontal region
Refractory to polytherapy
Val455Ile Multifocal spike wave, SSW, PSSW, AH, SB Periventricular leukomalacia Refractory to polytherapy
Thr532Lys Multifocal spike wave, SSW, PSSW, AH CCH white matter reduction in posterior horn of lateral ventricle Refractory to polytherapy
Ser534Leu Focal activity evolving to intermittent multifocal spikes and generalized SB Periventricular WML with compensatory dilation of lateral and third 
ventricles
Refractory to polytherapy
Val536Met Potentially epileptogenic activity throughout recording (1), not tested (7) Marked supra- and infratentorial atrophy, TCC, CA (2), 
ventriculomegaly (1), cortical atrophy, WML (1), not tested (6)
Well controlled on monotherapy (2), refractory to polytherapy (6)
Gly544Arg SB, temporal spikes (1), high- amplitude spikes, generalized spike and polyspike 
waves (1)
CCH, increased FLAIR signal in white matter (1), normal (1) Refractory to polytherapy until lamotrigine added (1), refractory (not 
fully responsive to medications) at 14 months (1)
Leu625Phe Multifocal or generalized sharp waves, spike waves, SSW, polyspike waves IH Normal (2 years), CA (4 years) Refractory to polytherapy until lamotrigine added
Ile626Asnfs*135 Not tested (2) Not tested (2) Controlled on monotherapy medication ceased by 7– 10 years of age (2)
chrX: g.(10182428_10187807)_(10189796_10201480) del 
mat
Bioccipital spikes, generalized spikes, generalized SB (1), normal (1) DM, TCC, global cerebral atrophy, particularly affecting the cerebral 
white matter (1), normal (1)
Refractory to polytherapy (1), controlled on levetiracetam 
monotherapy (1)
Arg718Trp SB, IH, multifocal spike waves, PSSW, SSW (1), multifocal discharges (1), not 
tested (1)
TCC (2), white matter reduction, small left hippocampus, left 
ventriculomegaly, DM (1), normal (1)
Refractory to polytherapy, but one finally remitted (2), not treated (1)
Abbreviations: ABS, abnormal Babinski signs; AH, atypical hypsarrhythmia; BSF, broad square forehead; CA, cerebellar atrophy; CCH, corpus callosum hypoplasia;  
CP, complex partial; CVI, cortical visual impairment; DM, delayed myelination; DNB, depressed nasal bridge; EE, epileptic encephalopathy; EEG,  
electroencephalogram; EIMFS, epilepsy of infancy with migrating focal seizures; FD, feeding difficulties; FLAIR, fluid- attenuated inversion recovery; FS, focal  
seizures; GS, generalized seizures; GT, generalized tonic; GTC, generalized tonic– clonic; ID, intellectual disability; IH, intermittent hypsarrhythmia; IS, infantile  
spasms; LD, language delay; M, myoclonic; NA, not available; NR, not reported; NV, nonverbal; PC, prominent chin; PS, progressive spasticity; PSSW, polyspike  
and slow waves; SB, slow background; SSW, spike and slow waves; T, tonic; TCC, thin corpus callosum; WML, white matter loss.
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results further indicate that CLCN4 variants are associated 
with a wide phenotypical spectrum varying from mild brief 
absence seizures to severe EE. The seizure onset was within 
the first year of life in 69.57% of individuals, indicating an 
infantile onset epilepsy. EE was diagnosed in 62.5% of pa-
tients, including IS, EIMFS, and unclassifiable EE. All pa-
tients presented ID, which was more severe in individuals 
with more severe seizure phenotypes. Moreover, cognitive 
outcome was worse in patients with CLCN4- related epi-
lepsy than in those without epilepsy. This suggests that ID 
is a common comorbidity of CLCN4- related epilepsy and se-
vere epilepsy may negatively influence cognitive outcome. 
However, cognition and development did not improve in 
most patients after seizure control. This suggests that cog-
nitive impairment was partially irreversible, possibly due to 
the negative effect of ClC- 4 dysfunction on cognition. Our 
data also underline that epilepsy outcome is highly variable 
between patients with CLCN4- related epilepsy. Only one pa-
tient did not undergo any treatment, and 43.48% of patients 
remitted. Seizure- related death was observed in four patients, 
suggesting a relevant risk for premature and unexpected 
death with CLCN4- related epilepsy. Seizure semiology was 
variable, including myoclonic, absence, tonic, complex par-
tial, tonic– clonic, focal, and secondary generalized seizures 
and IS, notably at the time of reporting, as it is not possible to 
capture the full seizure spectrum. Of note, there was a trend 
for patients with multiple seizure types to be more pharma-
coresistant than those with a single seizure type. To date, 
there are few data on treatment response in CLCN4- related 
epilepsy. Causal treatment is not available. The limited data 
suggest that CLCN4- related epilepsy is difficult to treat 
but has responded relatively well to lamotrigine, a blocker 
of voltage- sensitive sodium channel that reduces neuronal 
excitability, suggesting that the targets of lamotrigine and 
ClC- 4 are coexpressed in the same brain areas. Interestingly, 
our patients did not react to valproic acid, which exerts vari-
ous pharmacodynamic effects, for example on ionic currents 
and γ- aminobutyric acid levels.34 Lamotrigine abrogated or 
dramatically reduced seizures in five patients. Therefore, la-
motrigine should be considered as a therapeutic option for 
CLCN4- related epilepsy in the future. However, these ben-
eficial effects were seen in few patients, and larger prospec-
tive studies are needed to identify more effective therapeutic 
regimens. We also observed behavioral problems in almost 
half of the cases, with aggression being the most common. 
Neurological disturbances included microcephaly and in-
fantile hypotonia as the most prominent features. The fa-
cial dysmorphisms found in most patients did not provide 
a recognizable pattern or any facial features suggestive for 
CLCN4 variants. In addition, most individuals demonstrated 
structural brain abnormalities as detected by neuroimaging, 
but with no apparent pattern among the affected individu-
als. Nevertheless, corpus callosum abnormalities and white 
matter change were recurrent findings. The relationship of 
both white matter impairment and callosal abnormalities to 
epilepsy or DD will be important for future studies. However, 
no obvious changes were observed in white matter or corpus 
callosum of ClC- 4- deficient mice.8,23,35
Although mutations were found throughout the gene or 
the protein, a significant number of mutations were identified 
in Exon 11 of the CLCN4 gene, or located in the H- IM and 
CBS domains of the ClC- 4 protein, underlining the crucial 
importance of these regions. However, no obvious correla-
tion between the position of mutations on the gene or pro-
tein and severity of the phenotype was observed. We found 
two recurrent missense variants, p.Gly544Arg and p.Arg-
718Trp, suggesting these areas are possible mutational “hot 
spots” in CLCN4. Remarkably, all CLCN4 variants lead to 
loss of function, whereas diseases associated with CLCN6 
and CLCN7 can also be caused by gain- of- function mutations 
that increase the current amplitude or alter voltage- dependent 
activation kinetics.10,36– 39 For CLCN4, it is notable that 
frameshift or intragenic deletion variants cause rather mild 
phenotypes, whereas missense variants cause more severe 
phenotypes. Moreover, early death occurred in four patients 
with missense variants, whereas it did not occur in patients 
with frameshift or intragenic deletion variants, which may 
suggest that perturbation of normal ClC- 4 protein function 
is more deleterious than a reduction in its abundance or a 
complete absence. Such reduced protein levels are expected 
for the frameshift and intragenic deletion variants, because 
the alteration is located before the last exon (Figure 1) and 
even production of a truncated ClC- 4 version will be largely 
prevented through nonsense- mediated decay. A possible ex-
planation is that defective proteins caused by missense muta-
tions could be more deleterious, whereas loss of function due 
to reduced protein may be compensated by other proteins. In 
addition, ClC- 4 mutants within ClC- 3/ClC- 4 heteromers may 
impinge on ClC- 3, for example, by affecting the common 
subcellular trafficking or ion transport by the other subunit, 
as shown for ClC- 7 dimers.40,41
Whereas de novo variants were associated with more 
severe ID and epileptic phenotype, patients with inherited 
variants had milder ID and epileptic phenotype. Notably, 
phenotypic variability was seen in both recurrent variants and 
within single families. A remarkable phenotypic variability 
was found for the recurrent p.Arg718Trp variant, with one 
carrier showing brief absence seizures without the need of 
treatment, whereas others had more severe EE. Particularly 
noteworthy were the discrepancies in seizure phenotype 
within single families in which different individuals pre-
sented with either well- controlled seizures on monotherapy 
or severe EE and early death. CLCN4- related epilepsy thus 
displays a remarkable phenotypic heterogeneity, indicating 
that the genotype– phenotype relationship remains com-
plex. This presents challenges for genetic counseling. The 
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mechanisms underlying phenotypic heterogeneity are unclear 
but may be explained by individual genetic background, ge-
netic modifiers, epigenetic effects, or environmental factors. 
Further studies are required to precisely define the correla-
tion between genotype and phenotype.
Electrophysiological studies revealed that all these mis-
sense variants reduced or abolished ClC- 4 currents,6,8,12 
consistent with loss of function underlying the epilepsy 
and cognitive defects. The number of dendritic branches 
and dendritic length are remarkably reduced in primary 
hippocampal neurons from Clcn4- null mice and in Clcn4 
knockdown mouse hippocampal or cortical neurons.6,42 
Therefore, ClC- 4 showed a significant effect on neuronal 
differentiation, which corroborates the notion that loss of 
ClC- 4 function may be the major pathogenic mechanism. 
However, this conclusion appears to conflict with an appar-
ent lack of neurological or behavioral phenotype, or altered 
brain morphology in Clcn4−/− mice.8,23,35 These findings 
raised the possibility that another vesicular CLC protein 
with exactly the same properties might compensate for the 
loss of ClC- 4 in Clcn4−/− mice. ClC- 4 colocalizes with ClC- 
3, with which it can form functional heteromeric ClC- 3/- 4 
complexes.23,30,32 Hence, the lack of an obvious phenotype 
in Clcn4−/− mice may be explained by ClC- 3 compensating 
for the loss of ClC- 4.43 On the other hand, additional de-
pletion of ClC- 4 augments the neurodegeneration observed 
in Clcn3−/− mice.23,44 It remains unclear how loss of ClC- 4 
function leads to epilepsy in human. Additional cases and 
further functional studies are required to clarify the mecha-
nism in CLCN4- related epilepsy.
In conclusion, this study expands the number of reported 
patients with CLCN4- related epilepsy and describes three 
novel loss- of- function variants. It provides an overview of 
all CLCN4- related epilepsy cases, comparing the epilepsy 
and developmental findings in 24 subjects. The phenotypic 
spectrum of CLCN4- related epilepsy includes medication- 
resistant seizures, ID, behavioral disorders, and congenital 
anomalies. Notably, patients with multiple seizure types, or 
missense or de novo variants showed more severe pheno-
type, whereas single seizure type, frameshift or intragenic 
deletion, or inherited variants were associated with milder 
phenotypes. However, genotype– phenotype relationships for 
CLCN4- related epilepsy are not straightforward. Phenotypic 
variability was observed in recurrent variants and within sin-
gle families. Loss of ClC- 4 function is the most likely un-
derlying disease mechanism. Further elucidation of disease 
mechanisms may facilitate the development of targeted treat-
ments, which are much needed for this drug- resistant genetic 
epilepsy.
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F I G U R E  2  Functional findings of the three novel CLCN4 variants identified in this study. (A) Western blot analysis of HEK293 cells 
expressing wild- type (WT) ClC- 4 and ClC- 4 variants. WT and mutant ClC- 4 proteins showed similar protein expression levels. β- actin was 
used as loading control. NC, negative control (mock- transfected). Values are expressed as mean ± SEM of five independent experiments. 
(B) Representative current traces recorded from HEK293T cells expressing either WT or mutant ClC- 4. (C) Comparison of current– voltage 
relationships between WT (black solid squares, n = 12) and the three CLCN4 variants (p.V455I [red solid circles, n = 11], p.T532K [blue solid 
triangles, n = 13], L625F [inverted green solid triangles, n = 12]). (D) Subcellular localization of human ClC- 4 variants heterologously expressed 
in HEK293T cells. ClC- 4WT and the respective mutant proteins localize mainly to the endoplasmic reticulum (ER) and show strong colocalization 
with the coexpressed ER marker calnexin (WT ClC- 4, n = 22; p.V455I ClC- 4, n = 23; p.T532K ClC- 4, n = 26; or L625F ClC- 4, n = 20). (E) 
Representative images of HEK293T cells heterologously coexpressing ClC- 4 variants with ClC- 3b. Colocalization of ClC- 3b and WT or all the 
three ClC- 4 mutants in cytoplasmic vesicles of HEK293T cells (WT ClC- 4, n = 20; V455I ClC- 4, n = 20; T532K ClC- 4, n = 17; or L625F ClC- 4, 
n = 19). Scale bars = 5 μm
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